Skip to content
buyWeak

Ryan Solomon bought $76k of EHAB

Chief Financial Officer at Enhabit, Inc.. 10,000 shares at an average of $7.64, traded Aug 8, 2025, filed Aug 11, 2025.

Conviction score
33
Value
$76k
10,000 shares
Holdings after
193,468
+5% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CFO
    +22
  • Trade size
    $76k at market
    +8
  • Relative to holdings
    Holdings up 5%
    +3
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0002048471-25-000003, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 8, 2025POpen-market purchase
Common Stock
+10,000$7.64$76k193,468Aug 11, 2025

Related signals

Other insiders at Enhabit, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
33Weak
EHABsell 2
Enhabit, Inc.
Collin McQuiddy
Chief Accounting Officer
$19k
1,403 shares
-26%
11Weak
EHABsell 210b5-1
Enhabit, Inc.
Julie Diane Jolley
EVP of Home Health Operations
$76k
5,586 shares
-4%
35Weak
EHABsell
Enhabit, Inc.
Collin McQuiddy
Chief Accounting Officer
$9,404
1,096 shares
-100%
34Weak
EHABbuy 2
Enhabit, Inc.
Jeffrey Bolton
director
$35k
4,000 shares
+4%
40Moderate
EHABbuy 2
Enhabit, Inc.
Stuart M McGuigan
director
$132k
15,000 shares
+47%
26Weak
EHABbuy
Enhabit, Inc.
Jeffrey Bolton
director
$77k
10,000 shares
+12%
43Moderate
EHABbuy 2
Enhabit, Inc.
Jeffrey Bolton
director
$83k
10,000 shares
+24%
26Weak
EHABbuy 2
Enhabit, Inc.
Erin Hoeflinger
director
$18k
2,000 shares
+7%
38Weak
EHABbuy 2
Enhabit, Inc.
Jeffrey Bolton
director
$82k
10,000 shares
+31%
15Weak
EHABsell
Enhabit, Inc.
Ronald Leroy Langham JR
EVP Clinical Excel. & Strategy
$5,586
634 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Ryan Solomon bought $76k of EHAB | InsiderTell